Mepolizumab versus placebo for asthma

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 7, 2015, Pages

  Powell, Colin ^a   Milan, Stephen J ^b   Dwan, Kerry ^c   Bax, Lynne ^d   Walters, Nicola ^e  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d LANCASHIRE CARE NHS FOUNDATION TRUST   (United Kingdom)

^e ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEPOLIZUMAB; PLACEBO; MONOCLONAL ANTIBODY;

ASTHMA; BACKACHE; BLADDER CARCINOMA; BRONCHITIS; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMPARATIVE STUDY; CONSTIPATION; DISEASE EXACERBATION; DISEASE SEVERITY; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITAL ADMISSION; HUMAN; HYDROCEPHALUS; INFUSION RELATED REACTION; LUNG LAVAGE; MYALGIA; NAUSEA; PEAK EXPIRATORY FLOW; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; SUDDEN CARDIAC DEATH; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VIRUS INFECTION; ADOLESCENT; ADULT; CHILD; DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; DISEASE PROGRESSION; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; QUALITY OF LIFE;

EID: 84957414816     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010834.pub2     Document Type: Review

References (174)

1. Buttner C, Lun A, Splettstoesser T, Kunkel G, Renz H. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. European Respiratory Journal 2003;21(5):799-803. [CRS-ID: 4900100000015258]
2. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway [comment]. American Journal of Respiratory and Critical Care Medicine 2003;167(2):199-204. [CRS-ID: 4900100000013790;: 4900100000013790]
3. Flood-Page PT, Menzies-Gow AN, Phipps S, Compton C, Walls C, Barnes NC, et al. Reduction of tissue eosinophils in mild atopic asthmatics by an anti-IL-5 monoclonal antibody (Mepolizumab) is associated with inhibition of tenascin deposition with the bronchial epithelial basement [Abstract]. American Journal of Respiratory and Critical Care Medicine 2002;165(Suppl 8):B42. [CRS-ID: 4900100000013133]
4. Flood-Page PT, Menzies-Gow AN, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. Journal of Clinical Investigation 2003;112(7):1029-36. [CRS-ID: 4900100000015627]
5. Kay AB, Flood-Page PT, Menzies-Gow AN, Robinson DS. Effect of anti-Il-5 (mezolizumab) on airway eosinophils in asthmatics. Allergy and Clinical Immunology International 2004;Suppl 1:298-301. [CRS-ID: 4900100000051661;: 4900100000051661]
6. Menzies-Gow AN, Flood-Page PT, Compton C, Walls C, Sehmi R, Robinson DS, et al. A double-blind placebo-controlled, parallel group study to assess the effect of mepolizumab (humanised monoclonal anti-il-5-antibody) on bone marrow and peripheral blood eosinophils and eosinophil progenitors in atopic asthmatics [Abstract]. American Journal of Respiratory and Critical Care Medicine. 2002; Vol. 165, issue Suppl 8:B50. [CRS-ID: 4900100000013192]
7. Menzies-Gow AN, Flood-Page PT, Sehmi R, Burman J, Hamid Q, Robinson DS, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. The Journal of Allergy and Clinical Immunology 2003;111(4):714-9. [CRS-ID: 4900100000015225;: 4900100000015225]
8. Phipps S, Flood-Page PT, Menzies-Gow AN, Wangoo A, Barnes N, Barkans J, et al. Anti-IL-5 (mepolizumab) reduces the expression of tenascin procollagen III and lumican in the reticular basement membrane of human atopic asthmatics [Abstract]. The Journal of Allergy and Clinical Immunology. 2003; Vol. 111, issue 2 Suppl:S278. [CRS-ID: 4900100000018828]
9. Flood-Page PT, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. American Journal of Respiratory and Critical Care Medicine 2007;176(11):1062-71. [CRS-ID: 4900100000021401]
10. Gupta S, Halder P, Hargadon B, Sousa A, Marshall RP, Wardlaw AJ, et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma [Abstract]. American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. [CRS-ID: 4900100000024535]
11. Haldar P, Brightling C, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab (Anti-IL5) and exacerbation frequency in refractory eosinophilic asthma [Abstract]. Proceedings of the American Thoracic Society International Conference; 2009 May 15-20; San Diego. American Journal of Critical Care and Respiratory Medicine. 2009; Vol. 179:A3638. [CRS-ID: 4900100000024597]
12. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine 2009;360(10):973-84. [CRS-ID: 4900100000023473]
13. Haldar P, Brightling CE, Singapuri A, Hargadon B, Gupta S, Monteiro W, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. The Journal of Allergy and Clinical Immunology 2014;133(3):921-3. [CRS: 4900126000009453; EMBASE: 2014156329; PUBMED: 24418480]
14. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. The Lancet 2000;356(9248):2144-8. [CRS-ID: 4900100000010079]
15. Ayars AG, Altman LC, Potter-Perigo S, Radford K, Wight TN, Nair P. Sputum hyaluronan and versican in severe eosinophilic asthma. International Archives of Allergy and Immunology 2013;161(1):65-73. [CRS-ID: 4900100000077338]
16. Ayars AG, Altman LC, Potter-Perigo S, Wight TN, Nair P. Sputum hyaluronan as a biomarker of airway remodeling in severe asthma [Abstract]. Journal of Allergy and Clinical Immunology. 2011; Vol. 127, issue 2 Suppl 1:AB8. [CRS-ID: 4900100000027030]
17. NCT00292877. The effects of a humanized anti-IL-5 monoclonal antibody (SB-240563) on asthma control, airway eosinophilia and the degree to which corticosteroid treatment can be reduced to maintain control. https://clinicaltrials.gov/ct2/show/NCT00292877 (accessed 16 January 2015). [CRS-ID: 4900100000020456]
18. Nair P, Pizzichini M, Kjarsgaard M, Inman M, Efthimiadis A, Pizzichini E, et al. Prednisone sparing effect of mepolizumab on eosinophilic bronchitis with or without asthma a randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A568[#509]. [CRS-ID: 4900100000023006]
19. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. New England Journal of Medicine 2009;360(10):985-93. [CRS-ID: 4900100000023472]
20. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. https://clinicaltrials.gov/ct2/show/NCT01691521 (accessed 16 January 2015). [CRS-ID: 4900126000001339]
21. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine 2014;371(13):1198-207. [CRS: 4900126000019751; EMBASE: 25199059; PUBMED: 25199059]
22. NCT01000506. A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma. https://clinicaltrials.gov/ct2/show/NCT01000506 (accesssed 16 January 2015). [CRS-ID: 4900126000001337]
23. Ortega H, Li H, Suruki R, Albers F, Gordon D, Yancey S. Cluster analysis and characterization of response to mepolizumab: A step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society 2014;11(7):1011-7. [CRS: 4900126000015693; PUBMED: 24983709]
24. Pavord I, Korn S, Howarth P, Bleecker E, Buhl R, Keene O, et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma [Abstract]. Proceedings of the European Respiratory Society 22nd Annual Congress; 2012 Sep 1-5; Vienna. European Respiratory Journal. 2012; Vol. 40, issue Suppl 56:36s [349]. [CRS-ID: 4900100000068022]
25. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. The Lancet 2012;380(9842):651-9. [CRS-ID: 4900100000063432]
26. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. Journal of Allergy and Clinical Immunology 1994;93(3):556-66. [CRS-ID: 4900100000004347]
27. Armentia A, Arranz M, Martin JM, de la Fuente R, Sanchez P, Barber D, et al. Evaluation of immune complexes after immunotherapy with wheat flour in bakers' asthma. Annals of Allergy 1992;69(5):441-4. [CRS-ID: 4900100000003916]
28. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59(7):701-8. [CRS-ID: 4900100000017042]
29. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England Journal of Medicine 2014;371(13):1189-97. [CENTRAL: 1013105; CRS: 4900126000019750; EMBASE: 25199060; PUBMED: 25199060]
30. NCT01691508. MEA115575: A randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab adjunctive therapy to reduce steroid use in subjects with severe refractory asthma. https://clinicaltrials.gov/ct2/show/NCT01691508 (accessed 15 July 2015). [CRS-ID: 4900126000001341]
31. Berger W, Gupta N, McAlary M, Fowler-Taylor A, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Annals of Allergy, Asthma & Immunology 2003;91(2):182-8. [CRS-ID: 4900102000000524;: 4900102000000524]
32. Blanken M, Rovers M, Sanders E, Bont L. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemporary Clinical Trials 2012;33(6):1287-92. [CRS-ID: 4900100000067009]
33. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New England Journal of Medicine 2013;368(19):1791-9. [CRS-ID: 4900100000077900;: 4900100000077900]
34. Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. American Journal of Respiratory and Critical Care Medicine 1997;155(6):1835-40. [CRS-ID: 4900100000005712]
35. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125(4):1378-86. [CRS-ID: 4900100000016325]
36. Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66(5):671-8. [CRS-ID: 4900100000026344]
37. Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62(2):149-53. [CRS-ID: 4900100000019948;: 4900100000019948]
38. Bryant DH, Burns MW, Lazarus L. Identification of IgG antibody as a carrier of reaginic activity in asthmatic patients. The Journal of Allergy and Clinical Immunology 1975;56(6):417-28. [CRS-ID: 4900100000024002]
39. Bryant DH, Burns MW, Lazarus L. The correlation between skin tests, bronchial provocation tests and the serum level of IgE specific for common allergens in patients with asthma. Clinical Allergy 1975;5(2):145-57. [CRS-ID: 4900100000023985]
40. Buhl R, Kunkel G, Soler M, Bensch G, Wolfe J, Noga O, et al. RhuMAb-25 improves asthma-specific quality of life in patients with allergic asthma. European Respiratory Journal 2000;16(Suppl 31):465s. [CRS-ID: 4900100000013847]
41. Buhl R, Soler M, Fox H, Ashby M, McAlary M, Cooper J, et al. Recombinant humanized monoclonal antibody (rhuMAb) E25 in the prevention of serious asthma exacerbations. European Respiratory Journal 2000;16(Suppl 31):277s. [CRS-ID: 4900100000013848]
42. Buhl R, Soler M, Matz J, Townley R, O'Brien J, Noga O, et al. Omalizumab provides long-term control in patients with moderate-to- severe allergic asthma. European Respiratory Journal 2002;20(1):73-8. [CRS-ID: 4900100000012867]
43. Bush RK, Taylor SL, Nordlee JA, Busse WW. Soybean oil is not allergenic to soybean-sensitive individuals. The Journal of Allergy and Clinical Immunology 1985;76(2 Pt 1):242-5. [CRS-ID: 4900100000001757]
44. Busse WW, Corren J, Lanier BQ, Mcalary M, Fowler-Taylor A, Della Cioppa G, et al. Omalizumab, Anti-Ige Recombinant Humanized Monoclonal Antibody, for the Treatment of Severe Allergic Asthma. The Journal of Allergy and Clinical Immunology 2001;108(2):184-90. [CRS-ID: 4900100000010636;: 4900100000010636]
45. Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine 2008;178(10):1002-8. [CRS-ID: 4900100000022833]
46. Caffarelli C, Sensi LG, Marcucci F, Cavagni G. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000;55(12):1142-7. [CRS-ID: 4900100000009985]
47. Castro M, Mathur S, Hargreave F, Xie F, Young J, Wilkins HJ, et al. Reslizumab in the treatment of poorly controlled asthma in patients with eosinophilic airway inflammation [Abstract]. Annals of Allergy, Asthma & Immunology 2010;105(5 Suppl):A43. [CRS-ID: 4900100000054093]
48. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. American Journal of Respiratory and Critical Care Medicine 2011;184(10):1125-32. [CRS-ID: 4900100000056192]
49. Chandra RK, Singh G, Shridhara B. Effect of feeding whey hydrolysate, soy and conventional cow milk formulas on incidence of atopic disease in high risk infants. Annals of Allergy 1989;63(2):102-6. [CRS-ID: 4900100000002896]
50. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Annals of Allergy, Asthma & Immunology 2003;91(2):160-7. [CRS-ID: 4900100000015346;: 4900100000015346]
51. Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998;53(5):493-8. [CRS-ID: 4900100000023536]
52. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. The Journal of Allergy and Clinical Immunology 2003;111(1):87-90. [CRS-ID: 4900100000015187]
53. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. American Journal of Respiratory and Critical Care Medicine 2010;181(8):788-96. [CRS-ID: 4900100000024877]
54. Cullell-Young M, Bayes M, Leeson PA. Omalizumab: Treatment of allergic rhinitis, treatment of asthma. Drugs of the Future 2002;27(6):537-45. [CRS-ID: 4900100000050549]
55. De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen IJ, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: A randomized trial. The Journal of Allergy and Clinical Immunology 2014;133(4):989-996. [CENTRAL: 984687; CRS: 4900126000011203; EMBASE: 2014224342; PUBMED: 24582316]
56. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. American Journal of Respiratory and Critical Care Medicine 2004;170(6):583-93. [CRS-ID: 4900100000017162]
57. Ebner H, Neuchrist C, Havelec L, Kraft D. [Comparative studies of the effectiveness of specific immunotherapy in house dust mite allergy] [Vergleichende Untersuchungen zur Wirksamkeit einer spezifischen Immuntherapie bei Hausstaubmilben-Allergie]. Wiener Klinische Wochenschrift 1989;101(15):504-11. [CRS-ID: 4900100000002906]
58. Eckman JA, Sterba PM, Kelly D, Alexander V, Liu MC, Bochner BS, et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. The Journal of Allergy and Clinical Immunology 2010;125(4):889-895.e7. [CRS-ID: 4900100000024734]
59. El-Nawawy AA, Massoud MN, El-Nazzar SY, Ramy BB. Pulmonary tuberculosis as a cause of recurrent wheezy chest: the value of serological diagnosis using IgG antibodies to mycobacterium 38 kDa antigen. Journal of Tropical Pediatrics 2000;46(1):53-4. [CRS-ID: 4900100000008353]
60. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine 1997;155(6):1828-34. [CRS-ID: 4900100000005711]
61. Fahy JV, Cockcroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE, et al. Effect of aerosolized anti-IgE (E25) on airways responses to inhaled allergen in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine 1999;160(3):1023-7. [CRS-ID: 4900100000006519;: 4900100000006519]
62. Finn A, Gross G, Van Bavel J, Lee T, Windom H, Everhard F, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. The Journal of Allergy and Clinical Immunology 2003;111(2):278-84. [CRS-ID: 4900100000013800]
63. Frew AJ. Effects of anti-IgE in asthmatic subjects. Thorax 1998;53(Suppl 2):S52-7. [CRS-ID: 4900100000010183;: 4900100000010183]
64. Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé C, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 2013;144(2):411-9. [CENTRAL: 872766; CRS: 4900100000089187; EMBASE: 2013508319; PUBMED: 23579324]
65. Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. American Journal of Respiratory and Critical Care Medicine 2011;183(8):1007-14. [CRS-ID: 4900100000026369]
66. Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. New England Journal of Medicine 2014;370(22):2102-10. [CENTRAL: 991614; CRS: 4900126000014666;: 4900126000014666; PUBMED: 24846652]
67. Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Mayers I, Carlsten C, et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clinical and Experimental Allergy 2014;44(1):29-37. [CENTRAL: 961627; CRS: 4900126000003111; EMBASE: 2013812052; PUBMED: 24224471]
68. Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Science Translational Medicine 2014;6(243):243ra85. [CENTRAL: 994063; CRS: 4900126000015683; PUBMED: 24990880]
69. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. The Journal of Allergy and Clinical Immunology 2013;131(1):110-6.e1. [CRS-ID: 4900100000072110]
70. Gordon VH, Caplinger KJ, Meade JHJ, Thompson C. Correlation of type specific fluorescent antibodies to ragweed with symptomatology: double-blind study. Annals of Allergy 1972;30(9):507-17. [CRS-ID: 4900100000000354]
71. Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ. Randomized, double-blind phase II study of anti-endotoxin antibody (E5) as adjuvant therapy in humans with serious gram-negative infections. Progress in Clinical and Biological Research 1991;367:179-86. [CRS-ID: 4900100000003509]
72. Han JQ, Zhu YX. Efficacy and regulation of humoral immunity of jade screen powder as an adjunct therapy in children with asthma. Zhongguo Dang Dai Er Ke Za Zhi [Chinese Journal of Contemporary Pediatrics] 2009;11(7):587-8. [CRS-ID: 4900100000024253]
73. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial [Summary for patients]. Annals of Internal Medicine 2011;154(9):573-82. [CRS-ID: 4900100000026408]
74. Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. American Journal of Respiratory and Critical Care Medicine 2013;187(8):804-11. [CRS-ID: 4900100000077549;: 4900100000077549]
75. Hanania NA, Noonan MJ, Corren J, Korenblat P, Zheng Y, Putnam W, et al. Efficacy and safety of lebrikizumab in severe uncontrolled asthma: Results from the lute and verse phase II randomized, double-blind, placebo-controlled trials. The Journal of Allergy and Clinical Immunology 2014;133(2 Suppl):AB402. [CENTRAL: 985853; CRS: 4900126000010490; EMBASE: 71351759]
76. Hill DJ, Smart IJ, Hosking CS. Specific cellular and humoral immunity in children with grass pollen asthma. Clinical Allergy 1982;12(1):83-9. [CRS-ID: 4900100000001231]
77. Hodsman P, Ashman C, Cahn A, De Boever E, Locantore N, Serone A, et al. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. British Journal of Clinical Pharmacology 2013;75(1):118-28. [CRS-ID: 4900100000070660]
78. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical and Experimental Allergy 2004;34(4):632-8. [CRS-ID: 4900100000016275]
79. Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration; International Review of Thoracic Diseases 2012;83(6):520-8. [CRS-ID: 4900100000062323]
80. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-16. [CRS-ID: 4900100000018078]
81. Humbert M, Berger W, Rapatz G, Turk F. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. Allergy 2008;63(5):592-6. [CRS-ID: 4900100000021856;: 4900100000021856]
82. Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 2009;64(1):81-4. [CRS-ID: 4900100000023513]
83. Jacquemin MG, Saint-Remy JM. Specific down-regulation of anti-allergen IgE and IgG antibodies in humans associated with injections of allergen-specific antibody complexes. Therapeutic Immunology 1995;2(1):41-52. [CRS-ID: 4900100000004951]
84. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. The Journal of Allergy and Clinical Immunology 2005;116(3):608-13. [CRS-ID: 4900100000019019]
85. Kang BC, Johnson J, Morgan C, Chang JL. The role of immunotherapy in cockroach asthma. Journal of Asthma 1988;25(4):205-18. [CRS-ID: 4900100000008263]
86. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. American Journal of Respiratory and Critical Care Medicine 2003;167(12):1655-9. [CRS-ID: 4900100000015121]
87. Kon OM, Sihra BS, Loh LC, Barkans J, Compton CH, Barnes NC, et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. European Respiratory Journal 2001;18(1):45-52. [CRS-ID: 4900100000011111;: 4900100000011111]
88. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clinical and Experimental Allergy 2009;39(2):271-9. [CRS-ID: 4900100000023284]
89. Kopp MV, Hamelmann E, Bendiks M, Zielen S, Kamin W, Bergmann KC, et al. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatric Allergy and Immunology 2013;24(5):427-33. [CENTRAL: 870929; CRS: 4900100000087210; EMBASE: 2013483684; PUBMED: 23799935]
90. Kulus M, Hebert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Current Medical Research and Opinion 2010;26(6):1285-93. [CRS-ID: 4900100000025421]
91. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Annals of Allergy, Asthma & Immunology 2003;91(2):154-9. [CENTRAL: 440250; CRS: 4900100000015345; PUBMED: 12952109]
92. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. The Journal of Allergy and Clinical Immunology 2009;124(6):1210-6. [CENTRAL: 731495; CRS: 4900100000024431; EMBASE: 2009623072; PUBMED: 19910033]
93. Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. The Journal of Allergy and Clinical Immunology 2013;132(5):1086-96.e5. [CENTRAL: 874819; CRS: 4900126000001561; EMBASE: 2013693094; PUBMED: 23866823]
94. Leynadier F, Doudou O, Gaouar H, Le Gros V, Bourdeix I, Guyomarch-Cocco L, et al. Effect of omalizumab in health care workers with occupational latex allergy. The Journal of Allergy and Clinical Immunology 2004;113(2):360-1. [CRS-ID: 4900100000016361]
95. Lizaso MT, Tabar AI, Garcia BE, Gomez B, Algorta J, Asturias JA, et al. Double-blind, placebo-controlled Alternaria alternata immunotherapy: in vivo and in vitro parameters. Pediatric Allergy and Immunology 2008;19(1):76-81. [CRS-ID: 4900100000021781]
96. Massanari M, Kianifard F, Zeldin R K, Geba G P. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma. Allergy and Asthma Proceedings 2009;30(5):534-9. [CENTRAL: 728392; CRS: 4900100000024363; PUBMED: 19467177]
97. Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. The Journal of Allergy and Clinical Immunology 2010;125(2):383-9. [CRS-ID: 4900100000024484]
98. Mathur S, Castro M, Hargreave F, Xie F, Wilkins HJ, Henkel T, et al. Efficacy of reslizumab in patients with poorly controlled eosinophilic asthma: subgroup analysis of patients with nasal polyps [Abstract]. Journal of Allergy and Clinical Immunology. 2011; Vol. 127, issue 2 Suppl 1:AB84. [CRS-ID: 4900100000026800]
99. Metzger WJ, Fick RB, Bush RK, Busse W, Casale T, Chodosh S. Corticosteroid (CS) withdrawal in a study of recombinant humanized monoclonal antibody to IgE (rhu MAbE25) [Abstract]. The Journal of Allergy and Clinical Immunology 1998;101(1 Suppl):S231. [CRS-ID: 4900100000023644]
100. Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. RhuMAb-E25 Study Group. New England Journal of Medicine 1999;341(26):1966-73. [CRS-ID: 4900100000007996]
101. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108(2):E36. [CRS-ID: 4900100000010744]
102. Modlin JF, Smith DH, Harding L. Clinical trials of bivalent A/New Jersey/76-A/Victoria/75 influenza vaccines in high-risk children. Journal of Infectious Diseases 1977;136(Suppl):S626-31. [CRS-ID: 4900100000000785]
103. Moss RB, Hsu YP, Kwasnicki JM, Sullivan MM, Reid MJ. Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: correlation of rye group I antigen-specific IgG1 with clinical response. The Journal of Allergy and Clinical Immunology 1987;79(2):387-98. [CRS-ID: 4900100000002212]
104. Nair P, Kjarsgaard M, Armstrong S, Efthimiadis A, O'Byrne PM, Hargreave FE. Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma. The Journal of Allergy and Clinical Immunology 2010;126(2):404-6. [CENTRAL: 759797; CRS: 4900100000025377; PUBMED: 20621343]
105. NCT00802438. Eosinophilic airway inflammation: relationship to remodeling and modulation by mepolizumab. https://clinicaltrials.gov/ct2/show/NCT00802438 (accessed 15 July 2015). [CRS-ID: 4900126000001344]
106. NCT01366521. A multicenter, open-label, dose ranging study to determine the pharmacokinetics and pharmacodynamics of mepolizumab administered intravenously or subcutaneously to adult asthmatic subjects with elevated blood eosinophil levels. https://clinicaltrials.gov/ct2/show/NCT01366521 (accessed 15 July 2015). [CRS-ID: 4900126000001335]
107. NCT01471327. A single blind, placebo controlled, parallel group, single ascending intravenous dose study to assess safety, olerability, pharmacokinetics and pharmacodynamics of SB-240563 (mepolizumab) in healthy japanese male subjects. https://clinicaltrials.gov/ct2/show/NCT01471327 (accessed 15 July 2015). [CRS-ID: 4900126000001343]
108. NCT01691859. MEA115666: A multi-centre, open-label, long term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial. https://clinicaltrials.gov/ct2/show/NCT01691859 (accessed 15 July 2015). [CRS-ID: 4900126000001338]
109. NCT01842607. MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials. https://clinicaltrials.gov/ct2/show/NCT01842607 (accessed 15 July 2015). [CRS-ID: 4900126000001336]
110. NCT02135692. Study 201312: a multi-centre, open-label, study of mepolizumab in a subset of subjects with a history of life threatening/seriously debilitating asthma who participated in the MEA115661 trial. http://clinicaltrials.gov/show/NCT02135692 (accessed 15 July 2015). [CRS: 4900126000021136]
111. NCT02293265. Identification and description of severe asthma patients in a cross-sectional study - the IDEAL study. http://clinicaltrials.gov/show/NCT02293265 (accessed 15 July 2015). [CRS: 4900126000021134]
112. Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respiratory Medicine 2008;102(10):1371-8. [CRS-ID: 4900100000023545]
113. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. International Archives of Allergy and Immunology 2003;131(1):46-52. [CRS-ID: 4900100000015254;: 4900100000015254]
114. Noga O, Hanf G, Kunkel G, Kleine-Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. International Archives of Allergy and Immunology 2008;146(1):66-70. [CENTRAL: 628876; CRS: 4900100000021809; PUBMED: 18087163]
115. Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. The Journal of Allergy and Clinical Immunology 2013;132(3):567-74.e12. [CENTRAL: 872124; CRS: 4900100000088876; EMBASE: 2013545353; PUBMED: 23726041]
116. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. The Journal of Allergy and Clinical Immunology 2004;114(2):265-9. [CRS-ID: 4900100000016686]
117. Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respiratory Research 2013;14(1):93. [CENTRAL: 871533; CRS: 4900100000090024; EMBASE: 2013599844;: 4900100000090024; PUBMED: 24050312]
118. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Ohno Y, Masamoto T, et al. Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis. Annals of Allergy, Asthma & Immunology 1997;79(3):213-20. [CRS-ID: 4900100000005807]
119. Ohman JLJ, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. The Journal of Allergy and Clinical Immunology 1984;74(3 Pt 1):230-9. [CRS-ID: 4900100000007076]
120. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M, 1304 Study Group. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology 2009;14(8):1156-65. [CRS-ID: 4900100000024432]
121. Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou TT, Ying S, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. The Journal of Allergy and Clinical Immunology 2005;116(3):558-64. [CRS-ID: 4900100000019018]
122. Parker J, Brazinsky S, Miller DS, Nayak A, Korenblat PE, Sari S, et al. Randomized, double-blind, placebo-controlled, multicenter phase 2A study to evaluate the effect of a humanized interleukin-9 monoclonal antibody (MEDI-528) on exercise-induced bronchospasm [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A5394. [CRS-ID: 4900100000025282]
123. Pauli G, Bessot JC, Bigot H, Delaume G, Hordle DA, Hirth C, et al. Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial. The Journal of Allergy and Clinical Immunology 1984;74(4 Pt 1):524-35. [CRS-ID: 4900100000007226]
124. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. European Respiratory Journal 2013;41(2):330-8. [CRS-ID: 4900100000073595]
125. Prieto L, Gutierrez V, Colas C, Tabar A, Perez-Frances C, Bruno L, et al. Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma. International Archives of Allergy and Immunology 2006;139(2):122-31. [CRS-ID: 4900100000019265]
126. Pui M, Lay JC, Alexis NE, Carlsten C. Flow cytometry to identify leukocyte sub-populations in blood and induced sputum in asthmatic and healthy volunteers exposed to diesel exhaust [Abstract]. Allergy, Asthma, and Clinical Immunology 2010;6(Suppl 3):P7. [CRS-ID: 4900100000054152]
127. Rose MA, Gruendler M, Schubert R, Kitz R, Schulze J, Zielen S. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics. Vaccine 2009;27(38):5259-64. [CRS-ID: 4900100000024282]
128. Sakamoto Y, Nakagawa T, Ito K, Miyamoto T. Solid-phase radioimmunoassay for the measurement of IgG antibodies specific for the house dust mite, Dermatophagoides farinae. Annals of Allergy 1984;52(4):303-8. [CRS-ID: 4900100000008622]
129. Scheerens H, Arron J R, Su Z, Zheng Y, Putnam W, Erickson RW, et al. Predictive and pharmacodynamic biomarkers of interleukin-13 blockade: effect of lebrikizumab on late phase asthmatic response to allergen challenge [Abstract]. The Journal of Allergy and Clinical Immunology. 2011; Vol. 127, issue 2 Suppl 1:AB164. [CRS-ID: 4900100000026957]
130. Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clinical and Experimental Allergy 2014;44(1):38-46. [CENTRAL: 961626; CRS: 4900126000003110; EMBASE: 2013812053; PUBMED: 24131304]
131. Siergiejko Z, Swiebocka E, Smith N, Peckitt C, Leo J, Peachey G, et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Current Medical Research and Opinion 2011;27(11):2223-8. [CRS-ID: 4900100000056233]
132. Silk H, Zora J, Goldstein J, Tinkelman D, Schiffman G. Response to pneumococcal immunization in children with and without recurrent infections. Journal of Asthma 1998;35(1):101-12. [CRS-ID: 4900100000008189]
133. SilkoffPE, Romero FA, Gupta N, Townley RG, Milgrom H. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics 2004;113(4):e308-12. [CRS-ID: 4900100000016337]
134. Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. Journal of Pediatrics 2007;151(1):34-42, 42.e1. [CRS-ID: 4900100000023930]
135. Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulmonary Medicine 2010;10:3. [CRS-ID: 4900100000024732]
136. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. The Journal of Allergy and Clinical Immunology 2009;123(1):107-113.e3. [CRS-ID: 4900100000022846;: 4900100000022846]
137. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. European Respiratory Journal 2001;18(2):254-61. [CRS-ID: 4900100000011115]
138. Sorkness CA, Wildfire JJ, Calatroni A, Mitchell HE, Busse WW, O'Connor GT, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. The Journal of Allergy & Clinical Immunology in Practice 2013;1(2):163-71. [CENTRAL: 991371; CRS: 4900126000012068; PUBMED: 24565455]
139. Sthoeger ZM, Eliraz A, Asher I, Berkman N, Elbirt D. The beneficial effects of Xolair (Omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV - The Israeli arm of the INNOVATE study. Israel Medical Association Journal 2007;9(6):472-5. [CRS-ID: 4900100000021263]
140. Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA 1994;272(14):1122-6. [CRS-ID: 4900100000004523]
141. Swanson BN, Wang L, Ming J, Hamilton JD, Teper A, Dicioccio T, et al. Exhaled nitric oxide (FENO) and t-helper 2 cell biomarkers: can they predict treatment response to dupilumab, an il-4ra antibody, in an eosinophilic asthma population?. The Journal of Allergy and Clinical Immunology 2014;133(2 Suppl):AB85. [CENTRAL: 985863; CRS: 4900126000010595; EMBASE: 71351035]
142. Szymaniak L. An attempt to block histamine release from basophils granulocytes with antibodies obtained as a result of long-term immunization [Proba blokowania uwalniania histaminy z granulocytow zasadochlonnych przeciwcialami uzyskanymi w wyniku dlugotrwalej immunizacji bakteriami]. Annales Academiae Medicae Stetinensis 1998;44:45-64. [CRS-ID: 4900100000006192]
143. Tanaka Y, Ueda K, Miyazaki C, Nakayama M, Kusuhara K, Okada K, et al. Trivalent cold recombinant influenza live vaccine in institutionalized children with bronchial asthma and patients with psychomotor retardation. Pediatric Infectious Disease Journal 1993;12(7):600-5. [CRS-ID: 4900100000004155]
144. Terr AI. Immunologic bases for injection therapy of allergic diseases. Medical Clinics of North America 1969;53(6):1257-64. [CRS-ID: 4900100000000151]
145. Van Rensen EL, Evertse CE, Van Schadewijk WA, Van Wijngaarden S, Ayre G, Mauad T, et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009;64(1):72-80. [CRS-ID: 4900100000023512]
146. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59(7):709-17. [CRS-ID: 4900100000017155]
147. Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GD, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. The Journal of Allergy and Clinical Immunology 2003;111(5):952-7. [CRS-ID: 4900100000015247]
148. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. American Journal of Respiratory and Critical Care Medicine 2009;179(7):549-58. [CRS-ID: 4900100000023441;: 4900100000023441]
149. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. New England Journal of Medicine 2013;368(26):2455-66. [CRS-ID: 4900100000076900]
150. Zetterstrom O, Fagerberg E, Wide L. An investigation of pollen extracts from different deciduous trees in patients with springtime allergy in Sweden. Acta Allergologica 1972;27(1):15-21. [CRS-ID: 4900100000008122]
151. Zhu R, Zheng Y, Putnam WS, Visich J, Eisner MD, Matthews JG, et al. Population-based efficacy modelling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy. The AAPS Journal 2013;15(2):559-70. [CRS-ID: 4900126000000432]
152. Zielen S, Lieb A, De La Motte S, Wagner F, de Monchy J, Fuhr R, et al. Omalizumab protects against allergen-induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma. International Archives of Allergy and Immunology 2013;160(1):102-10. [CRS-ID: 4900100000072111]
153. NCT01520051. The efficacy of mepolizumab treatment on rhinovirus induced asthma exacerbations. https://clinicaltrials.gov/show/NCT01520051 (accessed 15 July 2015). [CRS-ID: 4900126000001342]
154. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. http://clinicaltrials.gov/show/NCT02281318 (accessed 15 July 2015). [CRS: 4900126000021132]
155. Braman SS. The global burden of asthma. Chest 2006;130(1 Suppl):4S-12S.
156. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2014;69(Suppl. 1):i1-i192.
157. Centers for Disease Control and Prevention. Trends in asthma prevalence, health care, and mortality in the United States, 2001-2010. www.cdc.gov/nchs/data/databriefs/db94.htm (accessed 10 December 2012).
158. Centers for Disease Control and Prevention. Vital signs. www.cdc.gov/vitalsigns/asthma/(accessed 10 December 2013).
159. Clayton S. Paediatric asthma: overcoming barriers to an improved quality of life. British Journal of Nursing 2005; Vol. 14, issue 2:80-5.
160. Fuhlbrigge A, Peden D, Apter A, Boushey HA, Camargo CA Jr, Gern J, et al. Asthma outcomes: exacerbations. The Journal of Allergy and Clinical Immunology 2012;129(3 Suppl):S34-S48.
161. Gibson PG, Talbot PI, Hancock J, Hensley MJ. A prospective audit of asthma management following emergency asthma treatment at a teaching hospital. Medical Journal of Australia 1993;158:775-8.
162. Global Intitiative for Asthma. Pocket guide for asthma management and prevention (for adults and children older than 5 years). http://www.ginasthma.org/local/uploads/files/GINA_Pocket2013_May15.pdf (accessed 5 November 2013).
163. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
164. Kandane-Rathnayake RK, Matheson MC, Simpson JA, Tang MLK, Johns DP, Mészáros D, et al. Adherence to asthma management guidelines by middle-aged adults with current asthma. Thorax 2009;64(12):1025-31.
165. Krishnan V, Diette GB, Rand CS, Bilderback AL, Merriman B, Hansel NN, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. American Journal of Respiratory and Critical Care Medicine 2006;174(6):633-8.
166. Liu Y, Zhang S, Li DW, Jiang S-J. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One 2013; Vol. 8, issue 3:e59872. [DOI: 10.1371/journal.pone.0059872]
167. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004;59:469-78.
168. Health and Social Care Information Centre. Hospital Episode Statistics. www.hesonline.nhs.uk (accessed 10 December 2012).
169. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma (EPR 3). www.nhlbi.nih.gov/guidelines/asthma/(accessed 10 December 2012).
170. Patel S, Jarvelin MR, Little M. Systematic review of worldwide variations of the prevalence of wheezing symptoms in children. Environmental Health 2009;7:57. [DOI: doi.10.1186/1476-069X-7-57]
171. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
172. Cruz AA, Mantzouranis E, Matricardi PM, Minelli E, Aït-Khaled N, Bateman ED, et al. In: Bousquet N, Khaltaev N editor(s). Global Surveillance, prevention and control of chronic respiratory diseases. A comprehensive approach. Geneva: World Health Organization, 2007.
173. World Health Organization. Health topics: asthma. www.who.int/topics/asthma/en/(accessed 13 September 2011).
174. Wu F, Takaro TK. Childhood asthma and environmental interventions. Environmental Health Perspectives 2007;115(6):971-5.